IOVA - Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma
2024-02-20 07:30:00 ET
Summary
- Iovance Biotherapeutics' stock has increased over 50% since September, following positive news about its TIL therapy for advanced melanoma.
- The FDA has granted approval for Iovance's TIL therapy, named Amtagvi, for the treatment of advanced melanoma after anti-PD-1 and targeted therapy.
- Amtagvi has the potential to carve out a niche in the crowded melanoma treatment market, offering hope to patients with few options left.
Introduction
Iovance Biotherapeutics' ( IOVA ) stock is up over 50% since my "buy" recommendation in September....
Iovance Biotherapeutics: Amtagvi's Pioneering Approval Sets New Standards In Melanoma